Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Tulane University has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. The prosecution of this matter is conducted by 1 distinct examiner and 1 distinct art unit, reflecting a concentrated effort where the university's current patent office interactions are limited to a single administrative channel. This concentration suggests that the university's current patent strategy is focused on a single technical matter. Practitioners should recognize that the 1 distinct art unit involved will define the procedural standards for the entirety of the active portfolio.
The busiest examiner for the university is DEBERRY, REGINA M, who manages 1 busiest examiner pending office action. This figure is equal to the total of 1 pending office action for the portfolio, meaning this examiner is responsible for all active legal review. With only 1 distinct examiner involved, the university faces a singular set of examination standards for its current filing. Practitioners can observe that the 1 busiest examiner pending office action is the only active component of the portfolio, allowing for a highly targeted prosecution strategy focused on this individual's review.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DEBERRY, REGINA M | 1 | 50.2% | +30.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17925082 | ADJUVANTED CONJUGATE OPIOID VACCINE | DEBERRY, REGINA M | — |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17925082 | ADJUVANTED CONJUGATE OPIOID VACCINE | DEBERRY, REGINA M | 1647 | §112 | Final Rejection | — | Pending | Nov 14, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTulane University has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Regina M Deberry has the most, with 1 of Tulane University's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
